Cell Therapy News

The FDA published a safety advisory on the risk of T-cell malignancies among individuals receiving autologous chimeric antigen receptor T-cell therapy for the treatment of certain blood cancers.

President Joe Biden today announced his intention to appoint oncologist, researcher and educator, W. Kimryn Rathmell, MD, PhD, as director of the NCI.

This blog post provides answers to important questions about the upcoming respiratory viral seasons.

Black, Hispanic and white individuals treated with idecabtagene vicleucel for relapsed or refractory multiple myeloma experienced similar PFS and OS, according to study results published in Blood Advances.

MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, according to study results presented at ESMO Congress.

Novel targeted therapies have become standard treatment for chronic lymphocytic leukemia due to their ability to delay progression of this slow-growing malignancy.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

Adults undergoing chimeric antigen receptor T-cell therapy are at low risk for major adverse cardiovascular events, according to data published in JACC: CardioOncology.

A young girl growing up in revolutionary-era Iran had a clear but lofty goal — cure cancer.

Researchers from City of Hope have detailed results of preclinical studies designed to optimize the durability of chimeric antigen receptor T cells for advanced ovarian cancer.